DRG Epidemiology's coverage of clostridium difficile infection comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the incidence and prevalence of clostridium difficile infection for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's clostridium difficile infection forecast will answer the following questions:
Of all people diagnosed with clostridium difficile infection, how many in each country across the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of clostridium difficile infection over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following clostridium difficile infection patient populations:
Diagnosed Events-Hospital by Frequency
Clostridium Difficile Infection Diagnosed Events - Hospital
Clostridium Difficile Infection Diagnosed Events-Nursing Home
Comorbidities-Initial Events subpopulation(s)
Diagnosed Events-Nursing Home by Frequency
Diagnosed Events-Severity subpopulation(s)
Comorbidities-Recurrent Events subpopulation(s)
Initial Events-Severe Complicated subpopulation(s)
Initial Events-Severity subpopulation(s)
Recurrent Events-Severe Complicated subpopulation(s)
… and more (details available on request).
Note: coverage may vary by country and region.
- Clostridium Difficile Infection - Epidemiology - Mature Markets Data
- Key Findings
- Event Rate of Hospitalized Clostridium Difficile Infection per 1,000 People of All Ages in 2016 and 2026
- Relative Sizes of the Contributing Factors to the Trend in Hospitalized Events of Clostridium Difficile Infection over Ten-Year Forecast Period
- Analysis of Diagnosed Events of Clostridium Difficile Infection in the Countries Under Study, by Stage: 2016
- Key Findings
- Epidemiology Data
- Diagnosed Events: Hospitalized
- Diagnosed Hospitalized Events: Recurrent
- Diagnosed Hospitalized CDI Events Transferred from Nursing Home
- Drug-Treated Hospitalized Events
- Severity - Based on Literature Data with Strict Application of Criteria
- Severity- Based on Physician Survey
- Diagnosed Healthcare-Associated Events
- Diagnosed Healthcare-Associated Events: Recurrent
- Diagnosed Community-Associated Events
- Diagnosed CDI Events
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Clostridium Difficile Infection
- Studies Excluded from the Analysis of Clostridium Difficile Infection
- Risk/Protective Factors
- Risk/Protective Factors for Clostridium Difficile Infection
- Literature Review
Author(s): Devashri Mukherjee, MPH; Lade Ayodele
Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office.
Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.
Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets.
Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a Ph.D. in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.